Mitochondrial dynamics and metabolic regulation in cellular inflammation: From mechanisms to precision therapeutics¶

The finding¶

This is a review article, not a primary research study — it doesn't report new experimental data. Its contribution is synthesis: it pulls together current literature on how mitochondrial fission/fusion balance (largely governed by Drp1-driven fission versus fusion machinery) acts as a "metabolic checkpoint" that licenses NLRP3 inflammasome activation, and it catalogs how oxidized/ribonucleotide-containing mtDNA released from fragmented mitochondria acts as a hyper-immunogenic ligand for cGAS-STING and other cytosolic sensors. It also surveys pharmacological strategies (Drp1 inhibitors, GLP-1 agonists, mitochondrial transplantation, etc.) aimed at this axis across diseases like sepsis, osteoarthritis, and cancer.

Where it fits¶

For the SAMHD1 A565T model, this review speaks most directly to Arm 2 (mitochondrial) and its intersection with Arm 3 (nucleotide/NLRP3). Two threads are especially relevant: (1) the idea that fragmented mitochondria release mtDNA that is only immunogenic when "fragile" or oxidized — a concept that dovetails with our hypothesis that SAMHD1 dysfunction leads to dNTP-pool imbalance, oxidized mtDNA, and NLRP3 activation; and (2) the general framework linking mitochondrial quality control (fission/fusion, mitophagy) to cGAS-STING signaling, which is the backbone of our VDAC1/ISG15-BECN1 mitophagy-block hypothesis in Arm 2. This review doesn't test our specific nodes (VDAC1, ISG15-BECN1, POLG, MFN1/2, PINK1/Parkin), but it provides independent conceptual support that the mitochondrial-dynamics-to-inflammasome pipeline we're proposing is an active, biologically plausible axis being pursued broadly in the inflammation field.

Caveats¶

This is a narrative review, not new primary data — it synthesizes existing mechanisms rather than testing SAMHD1, ANKIB1, or any A565T-specific node.
The diseases discussed (sepsis, neuroinflammation, osteoarthritis, cancer) are not interferonopathies, so applicability to a chronic, low-grade IFN-tone condition like SAMHD1 A565T is inferential, not demonstrated.
No heterozygous partial-loss-of-function genetic model is discussed; the fission/fusion-NLRP3 licensing concept is drawn from acute injury/inflammation contexts, which may differ mechanistically from a chronic, dNTP-driven state.

What to watch¶

The key open question this raises for our model is whether the specific "fragile mtDNA" (oxidized, ribonucleotide-containing) concept described here can be mapped onto SAMHD1 A565T cells experimentally — i.e., does the dNTP excess in Arm 3 actually generate this particular class of hyper-immunogenic mtDNA, and does correcting mitochondrial fission/fusion balance modulate NLRP3 output in patient-relevant cells?

Source: Mitochondrial dynamics and metabolic regulation in cellular inflammation: From mechanisms to precision therapeutics — 2026.